Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
ADNOC Gas Targets Up to $4B Profit in 2026 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
CARLSBAD, Calif., Feb. 21, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that the Company plans to participate in two upcoming investor conferences.
- March 1, 2018, GenMark’s management is scheduled to participate in the BTIG Snowbird Healthcare Conference in Snowbird, UT. Due to the format of this event, no webcast is available.
- March 14, 2018 at 10:00am ET, GenMark’s management is scheduled to present at the Cowen & Co. 38th Annual Health Care Conference in Boston, MA. Interested parties can access the live and archived webcast at www.genmarkdx.com, under the investor relations section.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
